<DOC>
	<DOC>NCT01801176</DOC>
	<brief_summary>It's a monitoring study. The aim is to assess the progression free survival up to 3 years. Patients are not treated until progression. Search for scalability predictive factors and registration of treatments if progression.</brief_summary>
	<brief_title>Peripheral Primitive Fibromatosis</brief_title>
	<detailed_description />
	<mesh_term>Fibroma</mesh_term>
	<criteria>Peripheral primitive fibromatosis Adults patients Peripheral primitive fibromatosis proved by biopsy Peripheral primitive fibromatosis R2 resected for which monitoring is decided MRI realized before inclusion Patient information and informed consent signed Local recur Head and neck topography Primitive fibromatosis R0 or R1 resected Specific medical treatment of fibromatosis Patient already included in an other clinical trial with an experimental molecule Persons deprived of liberty Impossibility to submit to the trial's medical followup for psychological, geographical or socials reasons Previous history of cancer Counter indication to the realization of an MRI</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>proved by biopsy</keyword>
</DOC>